Escalon Medical (OTCMKTS:ESMC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
This table compares Escalon Medical and LivaNova’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Escalon Medical and LivaNova, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LivaNova has a consensus price target of $128.75, indicating a potential upside of 34.32%. Given LivaNova’s higher possible upside, analysts clearly believe LivaNova is more favorable than Escalon Medical.
Institutional and Insider Ownership
0.1% of Escalon Medical shares are held by institutional investors. Comparatively, 89.5% of LivaNova shares are held by institutional investors. 1.9% of Escalon Medical shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Escalon Medical and LivaNova’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Escalon Medical||$11.40 million||0.12||$580,000.00||N/A||N/A|
|LivaNova||$1.11 billion||4.18||-$189.40 million||$3.17||30.24|
Escalon Medical has higher earnings, but lower revenue than LivaNova.
Volatility and Risk
Escalon Medical has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
LivaNova beats Escalon Medical on 8 of the 11 factors compared between the two stocks.
About Escalon Medical
Escalon Medical Corp. develops, manufactures, markets, and distributes medical devices and pharmaceuticals in the area of ophthalmology in the United States and internationally. It offers A-Scan, which provides information about the internal structure of the eye; B-Scan, a diagnostic tool that supplies information to physicians where the media within the eye are cloudy or opaque; UBM, a high frequency/high resolution ultrasound device, which provides detailed information about the anterior segment of the eye; and pachymeter that measures the thickness of cornea. The company also provides color/fluorescein angiography digital imaging systems that are primarily used in detecting retinal problems in diabetic and elderly patients; distributes intraocular gas products, such as C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; and manufactures and distributes a patented disposable universal gas kit that delivers the gas from the canister to the patient. In addition, it offers disposable surgical packs that are used in vitreoretinal surgery; viscous fluid transfer systems and related disposable syringe products, which aid surgeons in the process of injecting and extracting silicone oil; and AXIS Image management system for managing images through the Web browser from various devices regardless of modality, manufacturer, or location. The company sells its products to medical institutions through independent sales representatives, a network of distributors, and internal sales employees. Escalon Medical Corp. was founded in 1987 and is based in Wayne, Pennsylvania.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Escalon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Escalon Medical and related companies with MarketBeat.com's FREE daily email newsletter.